Advancing Biosynthesis and Scale-Up: Canurta at Canada SynBio, New Partnerships, and Preclinical Progress

Canurta Presents at Ontario Genomics: Canada SynBio Conference

Photos from the Conference- Dr. Soubeyrand on the left and Dr. Boddington on the right.

Canurta's Research Associates, Dr. Eric Soubeyrand and Dr. Kelly Boddington, represented the company at Ontario Genomic's fourth annual Canada SynBio Conference, which focused on accelerating the growth and success of Canada's Engineering Biology community. Specifically, Dr. Soubeyrand pitched Canurta's novel polyphenol molecules and biosynthesis technology platform development. Dr. Boddington presented the company's poster on the synthesis of cannabis sativa bibenzyls. Canurta is looking forward to attending the world congress of polyphenols in late September.

Canurta Signs Agreements with TransBIOTech and Innofibre

Canurta Inc. closed its agreements with TransBIOTech and Innofibre. TransBIOTech is a technology transfer college centre specializing in Biotechnology and Innofibre has research expertise in the technological acceleration of bioprocesses and bioproducts. In these agreements, TransBIOTech and Innofibre will assist Canurta in preclinical work and the scale-up of the extraction technology, respectively, which will add substantial value to the company. Moreover, these agreements are funded by the Natural Sciences and Engineering Research Council of Canada and can be renewed annually for three (3) years. Canurta's Quality Assurance Manager, Cameron Parry, is presently visiting Innofibre as preparation for the scale-up begins.

Photos from Innofibre extraction technology scale-up.

Canurta will be ramping up production during the summer months

Canurta Inc. will be ramping up production of its Activated Hemp Seed Powder during the summer months as they will be entering the market in the Fall.

Canurta is looking for bakers and formulators to assist in the production of pet treats. If you are interested or know someone who might be interested, please email us at investors@canurta.com.

Canurta is thrilled about its project with Applied Pharmaceutical Innovation (API). The preliminary data validates that our cannflavins have activity that may eventually help treat or prevent indications such as affect Systemic Chronic Inflammation, Chronic Pain, Arthritic issues, various Brain Health and Age-Related diseases, and, most surprisingly, COVID-19. We are extremely excited to continue learning about what these molecules can do and develop our target product pipeline and initial lead candidate product that can be taken into clinical study.